
    
      The results of our preliminary pilot study suggested that sorafenib combined with hepatic
      arterial infusion chemotherapy (HAIC) may improve the survivals for advanced stage HCC. Thus,
      the investigators carried out this prospective randomized control study to find out it.
    
  